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HydroCoils Reduce Recurrence Rates in Recently
RupturedMedium-Sized Intracranial Aneurysms:
A Subgroup Analysis of the HELPS Trial
W. Brinjikji, P.M. White, H. Nahser, J. Wardlaw, R. Sellar, H.J. Cloft, and D.F. Kallmes
ABSTRACT
BACKGROUND AND PURPOSE: The HydroCoil Endovascular Aneurysm Occlusion and Packing Study (HELPS) was a randomized, con-
trolled trial comparing HydroCoils with bare-platinum coils. The purpose of this study was to perform a subgroup analysis of angiographic
and clinical outcomes of medium-sized aneurysms in the HELPS trial.
MATERIALS AND METHODS: Patients with medium-sized aneurysms (5–9.9 mm) were selected from the HELPS trial. Outcomes com-
pared between the HydroCoil and bare-platinum groups included the following: 1) any recurrence, 2) major recurrence, 3) retreatment, and
4) mRS score of2. Subgroup analysis by rupture status was performed. Multivariate logistic regression analysis adjusting for aneurysm
neck size, shape, use of adjunctive device, and rupture status was performed.
RESULTS: Two hundred eighty-eight patients with medium-sized aneurysms were randomized (144 in each group). At 15–18 months
posttreatment, the major recurrence rate was significantly lower in the HydroCoil group than in controls (18.6% versus 30.8%, P  .03,
respectively). For patients with recently ruptured aneurysms, the major recurrence rate was significantly lower for the HydroCoil group
than for controls (20.3% versus 47.5%, P .003), while rates were similar between groups for unruptured aneurysms (16.7% versus 14.8%, P
.80). Multivariate analysis of patients with recently ruptured aneurysms demonstrated a lower odds of major recurrence with HydroCoils
(OR 0.27; 95% CI, 0.12–0.58; P .0007). No difference in retreatment rates or mRS of2 was seen between groups.
CONCLUSIONS: HydroCoils were associated with statistically significant and clinically relevant lower rates of major recurrence for
recently ruptured, medium-sized aneurysms in the HELPS trial. Because this was not a prespecified subgroup analysis, these results should
not alter clinical practice but, rather, provide insight into the design of future clinical trials comparing bare platinum with second-
generation coils.
ABBREVIATION: HELPS HydroCoil Endovascular Aneurysm Occlusion and Packing Study
Coil embolization of intracranial aneurysms is prone to recur-rence rates of up to 20%within 18 months of treatment.1 Up
to 10% of coiled aneurysms require retreatment, usually with ad-
ditional coil embolization. The costs and risks of monitoring an-
eurysms for recurrences and retreating them, when necessary, are
not negligible.2 Many modified coils have been developed aimed
at decreasing aneurysm recurrence and retreatment rates. Hydro-
gel coils (HydroCoil; MicroVention, Tustin, California) are de-
signed with an expansile hydrogel that fills more of the aneurysm
lumen than standard platinum coils.3 By doing so, these coils are
thought to achieve increased packing density thus accelerating
aneurysm healing and decreasing recurrence and retreatment
rates.4
The HydroCoil Endovascular AneurysmOcclusion and Pack-
ing Study (HELPS) was a randomized, controlled trial comparing
HydroCoils with bare platinum coils.5 This study compared the
rate of a composite primary outcome, which included both an-
giographic and clinical outcomes, between groups. The trial dem-
onstrated a 7.0% reduction in the proportion of adverse com-
posite primary outcomes with HydroCoils (P  .13), with
significantly higher rates of adverse outcomes in the control group
when only ruptured aneurysms were considered. In addition, the
investigators found a statistically significant, but not clinically
meaningful, difference in major angiographic recurrences be-
tween the HydroCoil and bare platinum groups.
While the HELPS trial represents level 1 evidence, the clinical
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applicability of the findings of the trial may be difficult to apply in
clinical practice.6 While the composite analysis has definite ben-
efits over exclusive focus on recurrence and treatment rates, this
composite end point has not been the usual metric used to eval-
uate the efficacy of aneurysm treatment. In addition, small aneu-
rysms have very low recurrence rates, and large aneurysms have
high recanalization rates, regardless of the device used.7 As such,
inclusion of small or large aneurysms may mask benefits isolated
to medium-sized aneurysms.8,9 Furthermore, ruptured aneu-
rysms have a different biology fromunruptured ones as evidenced
by elevated recurrence rates inmany series.10 To fully characterize
potential differences in “usual” outcomes between HydroCoil
and bare platinum coils, we performed a subgroup analysis of
angiographic and clinical outcomes of medium-sized aneurysms
in the HELPS trial, stratifying outcomes by rupture status. We
hypothesized that treatment with the HydroCoil would result in




Patients were enrolled in the HELPS trial from 24 centers in 7
countries. Patients were eligible for inclusion if they presented
with a previously untreated cerebral aneurysm measuring 2–25
mm in maximum diameter, were 18–75 years of age, were
deemed by the neurovascular team to need coiling, were not preg-
nant, had a World Federation of Neurosurgical Societies grade
between 0 and III, had anatomy in which endovascular occlusion
was judged possible, had not previously been enrolled in the trial,
and the neurointerventionalist whowould perform the procedure
was content to randomize to bare platinum coils or HydroCoils.
Patients were excluded if they had1 aneurysm requiring treat-
ment at 1 procedure. For the purposes of this subgroup analysis,
only the subset of patients with medium-sized (5.0–9.9 mm) an-
eurysms were included. All patients gave written informed con-
sent. If they could not give consent, then informed consent was
provided by a surrogate or legally authorized representative. This
trial had UK Multicenter Research Ethics Committee approval,
and all centers had local ethics approval. Detailed information
about the coiling procedure, randomization techniques, baseline
demographics, data handing, and coiling is shown elsewhere.5,11
Outcomes
The following baseline characteristicswere compared between the
HydroCoil and control groups: sex, age, dome-to-neck ratio, rup-
ture status, use of assist device, aneurysm shape, aneurysm loca-
tion (anterior versus posterior), and baselineWorld Federation of
Neurosurgical Societies score. For the purposes of this subgroup
analysis, we studied the following individual outcomes: any recur-
rence, major recurrence, mRS of 2, and retreatment. A major
recurrence was defined as a recurrence sufficiently large enough
to technically allow placement of further coils as defined by the
core laboratory assessing the angiograms.12 Retreatment was clas-
sified as any further treatment on the target aneurysm. mRS as-
sessment was performed by a postal questionnaire completed by
the patients or by theirmain caretaker andwas independent of the
interventional team. The above outcomes were studied at 2 sepa-
rate periods: 3–6months postcoiling and 15–18months postcoil-
ing. Analyses were performed comparing the rate of these out-
comes between patients randomized to the HydroCoil group and
those randomized to the control group (bare platinum coils). The
analyses included the following patient subgroups: 1) all patients
with medium aneurysms, 2) all patients with recently ruptured
aneurysms, and 3) all patients with non-recently ruptured/un-
ruptured aneurysms. Recently ruptured aneurysms were defined
as those that had ruptured within 30 days of treatment.
Statistical Analysis
All means are presented with their corresponding SDs. Compar-
ison between groups of these categoric outcomes was performed
byusing the Fisher exact test.Multivariate logistic regression anal-
yses were performed to determine whether differences between
the HydroCoil and control groups existed for the following out-
comes: 1) any recurrence at last follow-up, 2) major recurrence at
last follow-up, 3)mRS of2 at last follow-up, and 4) retreatment
at last follow-up.Multivariate logistic regression analyses, includ-
ing all patients with medium-sized aneurysms, were adjusted for
neck size, rupture status, aneurysm shape, and the use of an assist
device. When we performed subgroup analyses by rupture status,
the above-mentioned variables were included with the exception
of rupture status. Statistical analysis was performed by using JMP
10.0 Pro (www.jmp.com; SAS Institute, Cary, North Carolina).
Role of Funding Source
The sponsor/funder (MicroVention) had no part in the trial de-
sign, data collection, analysis, or reporting. These were organized
by the steering committee, whichwas independent of the sponsor.
The corresponding author had full access to all the data and had
final responsibility for the decision to submit the publication.
RESULTS
Patient and Aneurysm Characteristics
A total of 288 patients with medium-sized aneurysms were ran-
domized. There were no significant differences in any of the base-
line characteristics studied between groups. Of 144 patients in the
HydroCoil group, 74 (51.4%) had recently ruptured aneurysms;
and of the 144 patients in the control group, 75 (52.1%) had
recently ruptured aneurysms (P  1.00). Sixty-six aneurysms in
theHydroCoil groupwere treatedwith assist devices (46.2%) ver-
sus 63 patients in the control group (44.4%) (P .81). Therewere
no differences in the usage rate of balloon assistance (P .50) or
stent assistance (P  .63) between groups. Aneurysm shape did
not differ between groups because 43 patients (29.9%) in the
HydroCoil group had irregular-shaped aneurysms compared
with 38 patients (26.4%) in the control group (P .60). Therewas
no difference in aneurysm location (P .13). These data are sum-
marized in Table 1.
Outcomes: All Patients with Medium-Sized Aneurysms
At 3–6 months posttreatment, 114 patients (79.2%) in the
HydroCoil groupand115patients (79.9%) in the control grouphad
angiographic follow-up. There was a lower rate of any recurrence
in the HydroCoil group compared with the control group (23
patients, 20.2%, versus 35 patients, 33.3%; P .03). Major recur-
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rence rates did not differ between groups, however, as 11 patients
(9.6%) in the HydroCoil group had major recurrences versus 17
patients (16.2%) in the control group (P .16). At 15–18months
posttreatment, 113 patients (78.5%) in the HydroCoil group and
120 patients (83.3%) in the control group had angiographic fol-
low-up. Therewas a similar rate of any recurrence between groups
(40 patients, 35.4%, versus 55 patients, 45.8%;P .11).However,
the rate of major recurrence was significantly lower in the Hydro-
Coil group than in the control group (21 patients, 18.6%, versus
37 patients, 30.8%; P .03). No difference in retreatment rates or
mRS of 2 was seen between groups at either time point. These
data are summarized in Table 2.
Twelve patients in the medium aneurysm cohort died during
follow-up (6 in the bare platinum group and 6 in the HydroCoil
group). Of these, 8 died within 1 month of the procedure. Four
died because of subarachnoid hemorrhage; 1 death was due to
cardiac arrest and multiorgan failure; 1, due to bleeding of a
treated unruptured aneurysm; and 2, from ischemic complica-
tions secondary to vasospasmor intracranial hypertension. Of the
other 4 deaths, 1 was from gastric cancer, 1 was from bacterial
meningitis, 1 was due to a post-SAH stroke that resulted in the
patient being in a vegetative state, and 1 was from rebleed of a
treated ruptured aneurysm.
Outcomes: Patients with Recently Ruptured,
Medium-Sized Aneurysms
Among patients with recently ruptured aneurysms, at 3–6
months posttreatment, 56 patients in theHydroCoil group and 50
patients in the control group had angiographic follow-up. The
rate of any recurrence was lower in the HydroCoil group (14
patients, 25.0%, versus 24 patients, 38.0%; P  .02), as was the
rate of major recurrence (4 patients, 7.1%, versus 13 patients,
26.0%; P  .02). At 15–18 months posttreatment, 59 patients in
each group had angiographic follow-up. The rate of any recur-
rence was significantly lower in theHydroCoil group (22 patients,
37.3%, versus 38 patients, 64.4%; P  .006), as was the rate of
major recurrence (12 patients, 20.3%, versus 28 patients, 47.5%;
P .003). Therewas no difference in retreatment ormRSof2 at
either time point. These data are summarized in Table 3.
Table 1: Baseline characteristics of medium-sized aneurysms
HydroCoil Control P
Total patients (No.) 144 144 –
Sex
Female 100 (69.4) 102 (70.8) .90
Male 44 (30.6) 42 (29.2)
Age (yr)
45 or younger 42 (29.2) 49 (34.0) .57
46–55 43 (29.9) 44 (30.6)
Older than 55 59 (41.0) 51 (35.4)
Dome-to-neck ratio
1.5 43 (29.9) 50 (34.7) .45
1.5 101 (70.1) 94 (65.3)
Rupture status
Recently ruptured 74 (51.4) 75 (52.1) 1.0
Unruptured/not recently ruptured 70 (48.6) 69 (47.9)
Use of assist devicea
Yes 66 (46.2) 63 (44.4) .81
No 77 (53.9) 79 (55.6)
Balloon 39 (27.1) 33 (22.9) .50
Stent 27 (18.8) 31 (21.5) .66
Aneurysm shape
Irregular (multilobulated) 43 (29.9) 38 (26.4) .60
Not multilobulated 101 (70.1) 106 (73.6)
Aneurysm location
Anterior circulation 119 (82.6) 127 (88.2) .13
Posterior circulation 25 (17.4) 17 (11.8)
Baseline WFNS
0 67 (46.5) 64 (44.4) .76
I 66 (45.8) 64 (44.4)
II 9 (6.3) 14 (9.7)
III 2 (1.4) 2 (1.4)
Note:—WFNS indicates World Federation of Neurosurgical Societies.
a Data on assist device use were not available for 1 patient in the HydroCoil group and
2 patients in the control group.
Table 2: Angiographic and clinical results of all patients with medium-sized aneurysms









No. of patients with angiographic follow-up 114 115 – 113 120 –
No. of patients with clinical follow-up 124 119 – 128 129 –
Any recurrence 23 (20.2) 35 (33.3) .03a 40 (35.4) 55 (45.8) .11
Major recurrence 11 (9.6) 17 (16.2) 0.16 21 (18.6) 37 (30.8) .03a
Retreatment 1 (0.9) 2 (1.7) 1.0 3 (2.7) 5 (4.2) .72
mRS 2 107 (86.3) 106 (89.1) .56 113 (88.3) 116 (89.9) .69
a Significant.
Table 3: Angiographic and clinical results of patients with recently ruptured medium-sized aneurysms









No. of patients with angiographic follow-up 56 50 – 59 59 –
No. of patients clinical follow-up 63 64 – 65 65 –
Any recurrence 14 (25.0) 24 (48.0) .02a 22 (37.3) 38 (64.4) .006a
Major recurrence 4 (7.1) 13 (26.0) .02a 12 (20.3) 28 (47.5) .003a
Retreatment 0 (0.0) 0 (0.0) 1.0 0 (0.0) 2 (3.4) .50
mRS 2 54 (85.7) 56 (87.5) .80 56 (86.2) 59 (90.8) .58
a Significant.
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Outcomes: Patients with Non-Recently Ruptured
Aneurysms
Fifty-eight patients in the HydroCoil group and 55 patients in the
control group had angiographic follow-up at 3–6 months. The
rate of any recurrence was similar between groups as 15.5% of
patients treated with HydroCoil (9 patients) and 20.0% of con-
trols (11 patients) had a recurrence (P .62). The same was true
for major recurrences (7 patients, 12.1%, versus 4 patients, 7.3%,
respectively; P .53). At 15–18 months, 54 patients treated with
HydroCoils and 61 control patients had follow-up angiograms.
The recurrence rate was 33.3% for patients treated with Hydro-
Coils (18 patients) and 27.9% for controls (17 patients) (P .55).
No difference in major recurrence rates was seen between groups
(16.7%, 9 patients, versus 14.8%, 9 patients, respectively;P .80).
These data are summarized in Table 4.
Multivariate Analysis
Onmultivariate logistic regression analysis, when considering the
aneurysms of all patients (unruptured/non-recently ruptured and
recently ruptured), HydroCoil was associated with lower odds of
major recurrence (OR 0.54; 95% CI, 0.30–0.98; P .04). For
patients with recently ruptured aneurysms, HydroCoil was asso-
ciated with lower odds of any recurrence (OR  0.37; 95% CI,
0.18–0.76; P .006) and major recurrence (OR 0.27; 95% CI,
0.12–0.58; P .0007). There was a trend toward lower retreat-
ment rates in the recently ruptured group treated with Hydro-
Coils (OR  0.00; 95% CI, 0.00–2.01; P  .12). No difference
in recurrence rates was seen between coil types in the non-
recently ruptured/unruptured group. There were no differ-
ences in mRS of 2 between groups. These data are summa-
rized in Table 5.
DISCUSSION
This subgroup analysis of patients in the HELPS trial found that
HydroCoil is associated with statistically significant and clinically
relevant lower rates of recurrence compared with bare platinum,
specifically for major recurrence, among patients with medium-
sized, recently ruptured aneurysms. In addition, multivariate
analysis found lower rates of major recurrence with the Hydro-
Coil group for all aneurysms, even when adjusting for rupture
status. Subgroup analyses of patients with non-recently ruptured/
unruptured aneurysms found no difference in recurrence rates
between the HydroCoil and control groups. Overall, these data
strongly suggest that hydrogel coils, such as the HydroCoil, are
superior to bare platinum coils in the treatment of ruptured me-
dium-sized aneurysms. These findings could have substantial
therapeutic implications if validated in future trials because me-
dium-sized aneurysms accounted for nearly half of the patients
with ruptured aneurysms treated in the International Subarach-
noid Aneurysm Trial.13 This was not a prespecified subgroup
analysis; thus, these results should not serve to alter clinical prac-
tice at this time and need to be validated in future studies.
There are a few potential explanations for the association of
HydroCoils with superior occlusion rates compared with bare
platinum coils, specifically in ruptured aneurysms. The biology of
ruptured aneurysms differs substantially from that of unruptured
aneurysms. Ruptured aneurysms are, by definition, unstable and
more prone to growth and recurrence than unruptured aneu-
rysms.10 Hydrogel coils are designed with an expansile hydrogel
that fills more of the aneurysm lumen than standard platinum
coils. HydroCoils provide substantially improved volumetric
packing of the aneurysm lumen compared with standard bare
platinum coils.4,14 By expanding to fill the aneurysm lumen, these
coils may bemore effective at sealing the aneurysm rupture point,
a point of growth within the aneurysm. Furthermore, in an in
vitro study, Watanabe et al15 found that HydroCoils were more
effective than bare platinum coils in stopping outflow from the
rupture point of experimental aneurysms. These coils may also be
more effective at sealing the aneurysm neck as supported by his-
tologic studies in both rabbits and humans.16,17 In a study com-
paring the efficacy of HydroCoil, HydroSoft (MicroVention),
platinum, and Cerecyte coils (Codman Neurovascular, Rayn-
ham, Massachusetts) in angiographic and histologic occlusion
of aneurysms in a rabbit model, Killer et al18 found that hydro-
gel devices (ie, HydroCoil and HydroSoft) had significantly
Table 4: Angiographic and clinical results of patients with non-recently ruptured medium-sized aneurysms









No. of patients with angiographic follow-up 58 55 – 54 61 –
No. of patients with clinical follow-up 61 55 – 63 64 –
Any recurrence 9 (15.5) 11 (20.0) .62 18 (33.3) 17 (27.9) .55
Major recurrence 7 (12.1) 4 (7.3) .53 9 (16.7) 9 (14.8) .80
Retreatment 1 (1.7) 2 (3.6) .61 3 (5.6) 3 (4.9) 1.0
mRS 2 53 (86.9) 50 (90.9) .57 57 (90.5) 57 (89.1) 1.0
Table 5: Multivariate logistic regression analysisa
All Patients (OR) (95% CI)b P Recently Ruptured (OR) (95% CI)c P Non-Recently Ruptured (OR) (95% CI)c P
Any recurrence 0.72 (0.43–1.20) .21 0.37 (0.18–0.76) .006 1.58 (0.73–3.47) .25
Major recurrence 0.54 (0.30–0.98) .04 0.27 (0.12–0.58) .0007 1.55 (0.58–4.29) .38
mRS 2 1.08 (0.51–2.32) .83 0.96 (0.35–2.68) .94 1.23 (0.38–4.06) .73
Retreatment 0.51 (0.07–2.78) .44 0.00 (0.00–2.01) .12 0.97 (0.11–8.81) .98
a Odds of HydroCoil versus the control group.
b Adjusted for neck size, use of adjunctive device, aneurysm shape, and rupture status.
c Adjusted for neck size, use of adjunctive device, and aneurysm shape.
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higher rates of histologic and angiographic occlusion, which
increased with time. Increased healing was seen at both the
aneurysm neck and dome.
A number of previously published studies have compared the
efficacy of bare platinum andmodified coils. In ameta-analysis of
82 studies, Rezek et al19 compared the efficacy of bare platinum
coils with Matrix (Stryker, Kalamazoo, Michigan), HydroCoil,
and Cerecyte coils. They found no difference in the rate of unfa-
vorable angiographic outcomes among groups. This study was
limited in that they did not perform subgroup analyses by aneu-
rysm size and rupture status. Furthermore, a vast majority of the
included studies were noncontrolled case series, thus limiting the
level of evidence of these findings. Several single-center studies
have demonstrated thatHydroCoils are associatedwith decreased
recurrence rates compared with bare platinum coils; however,
none were randomized, controlled trials, and many were too
small for subgroup analyses to define which patients may benefit
themost fromHydroCoil treatment.20,21 A number of single-arm
studies have demonstrated high aneurysm-occlusion rates with
HydroCoils.22-24 The largest of these, theHydroCoil for Endovas-
cular Aneurysm Occlusion study, found high rates of initial and
long-term occlusion in a series of 191 aneurysms treated with
HydroCoils.25 The authors found relatively low rates of minor
and major recurrences among aneurysms of10 mm, similar to
the findings of our study.26 Our subgroup analysis of patients in
HELPS is the largest comparative analysis to date examining clin-
ical and angiographic results of medium-sized aneurysms, to our
knowledge.
Limitations
Our study has limitations. Subgroup analyses can be misleading
for a number of reasons.27 For example, if the overall result of a
trial is significant, then on the basis of chance, some subgroups
will have a positive result and some will have a negative result.
Also, if the overall result of a study is negative, on the basis of
chance alone, some subgroupsmay have a larger treatment effect.
Subgroup analyses should be based on hypotheses that make
sense biologically.27 On the basis of prior preclinical studies, we
thought that it was biologically plausible that HydroCoils would
be more effective in the treatment of ruptured aneurysms. Ulti-
mately, subgroup analyses are most helpful when they are pre-
specified in the trial design. Ours was not a prespecified subgroup
analysis for the HELPS trial; therefore, these data should not nec-
essarily alter clinical practice but rather serve as a guide for the
design of future trials comparing second-generation coils with
bare platinum coils. Another major flaw in subgroup analyses in
general is overemphasis of P values rather than the treatment
effect. Therefore, readers should examine the results of subgroup
analyses closely to determine whether the differences between
groups are clinically meaningful.28
No follow-up data on aneurysm recurrence and retreatment
were available beyond 18 months. Given the significantly higher
rate of major recurrence in the control group with medium-sized
ruptured aneurysms, it is conceivable that more of these patients
would go on to retreatment during the long-term follow-up. The
combination of low power and lack of consistent follow-up be-
yond 18 months likely contributes to the lack of statistical signif-
icance in the aneurysm retreatment rates between groups, despite
the higher rates of major recurrence in the control group. Not all
patients received angiographic and clinical follow-up. Of the 288
initially randomized patients with medium-sized aneurysms,
only 229 had angiographic follow-up at 3–6 months and 233 had
angiographic follow-up at 15–18 months. Last, we did not study
differences in packing attenuation between groups. Baseline fac-
tors, such as hypertension, which may be associated with aneu-
rysm recurrence, were not assessed in our analysis. In addition, we
did not study the types of recurrence (recurrence due to recana-
lization, regrowth, coil compaction, or coilmigration through the
aneurysm wall).
The aneurysm recanalization rate in our study was much
higher than that reported in other clinical studies and meta-anal-
yses studying postcoiling recanalization rates.9 The most likely
reason is that we used a core laboratory in the assessment of un-
favorable outcome, whereas in most clinical studies, clinical and
angiographic outcomes are not assessed by an independent core
laboratory. For example, in the Cerecyte Coil Trial, unfavorable
angiographic outcomes were noted twice as frequently by the in-
dependent core laboratory compared with the operators that per-
formed the procedure.29 In addition, in a meta-analysis of
15,000 treated aneurysms in 104 studies, Rezek et al30 found
that core laboratory studies reported statistically significant and
clinically meaningful higher rates of unfavorable outcomes than
self-reported studies.
CONCLUSIONS
Our subgroup analysis of patients with medium-sized aneurysms
in theHELPS trial found that treatment withHydroCoils resulted
in significantly lower rates of major recanalization in this popu-
lation. The benefits of HydroCoils were most marked in the me-
dium-sized, recently ruptured population. Because this was not a
prespecified subgroup analysis, these results should not serve to
alter clinical practice but, rather, provide insight into the design of
future clinical trials comparing bare platinum with second-gen-
eration coils.
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